Trial Profile

A Phase 1 clinical trial of KER-0193 in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KER 0193 (Primary)
Indications Fragile X syndrome
Focus Adverse reactions

Most Recent Events

14 May 2025 According to a Kaerus Bioscience media release, KER-0193 has been granted both Orphan Drug Designation and Rare Pediatric Drug Designations for the treatment of Fragile X syndrome (FXS) by the U.S. Food and Drugs Administration (FDA).
11 Mar 2025 Status changed from recruiting to completed,According to a Kaerus Bioscience media release.
29 Jul 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com